Targeting aerobic glycolysis by dichloroacetate improves Newcastle disease virus-mediated viro-immunotherapy in hepatocellular carcinoma
/in Hepatocellular Carcinoma, International Publications, Newcastle Disease Virus /von 2019-12-10 / Br. J. Cancer 2020 Jan;122(1):111-120Immunotherapy with dendritic cells and cytokine-induced killer cells for hepatocellular carcinoma: A meta-analysis
/in Dendritic Cells, Hepatocellular Carcinoma, International Publications /von 2019-07-21 / World J. Gastroenterol. 2019 Jul;25(27):3649-3663Hepatocellular carcinoma: Mechanisms of progression and immunotherapy
/in Dendritic Cells, Hepatocellular Carcinoma, International Publications /von 2019-07-07 / World J. Gastroenterol. 2019 Jul;25(25):3151-3167Immunotherapy for hepatocellular carcinoma: Current and future
/in Dendritic Cells, Hepatocellular Carcinoma, International Publications /von 2019-06-28 / World J. Gastroenterol. 2019 Jun;25(24):2977-2989A Potential Antitumor Effect of Dendritic Cells Fused with Cancer Stem Cells in Hepatocellular Carcinoma
/in Dendritic Cells, Hepatocellular Carcinoma, International Publications /von 2019-04-01 / Stem Cells Int 2019;2019:5680327Immunotherapeutic strategies for treatment of hepatocellular carcinoma with antigen-loaded dendritic cells: in vivo study
/in Dendritic Cells, Hepatocellular Carcinoma, International Publications /von 2018-07-30 / Clin. Exp. Med. 2018 Nov;18(4):535-546Immunotherapy of Hepatocellular Carcinoma
/in Checkpoint-Inhibitors, Dendritic Cells, Hepatocellular Carcinoma, International Publications, Newcastle Disease Virus /von 2018-04-20 / Oncol Res Treat 2018;41(5):292-297Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations
/in Dendritic Cells, Hepatocellular Carcinoma, International Publications /von 2018-03-26 / J Immunol Res 2018;2018:8740976EpCAM peptide-primed dendritic cell vaccination confers significant anti-tumor immunity in hepatocellular carcinoma cells
/in Dendritic Cells, Hepatocellular Carcinoma, International Publications /von 2018-01-03 / PLoS ONE 2018;13(1):e0190638
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Long-term follow up of patients with mesothelioma treated with dendritic cell therapy in three phase I trials.
- Phase 1 trial of autologous dendritic cell vaccination with imiquimod immunomodulation in children and adults with refractory sarcoma.
- Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma